{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:35:03Z","timestamp":1787506503578,"version":"build-2736575974"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T00:00:00Z","timestamp":1765670400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology Case Reports"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.eucr.2025.103317","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:10:52Z","timestamp":1765815052000},"page":"103317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Early-onset fatal toxic epidermal necrolysis after first-cycle enfortumab vedotin in an elderly patient with metastatic urothelial carcinoma"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7240-6113","authenticated-orcid":false,"given":"Fumihiro","family":"Ito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurika","family":"Sawasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaku","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Kamijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitaka","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"29","key":"10.1016\/j.eucr.2025.103317_bib1","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti\u2013PD-1\/PD-L1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.eucr.2025.103317_bib2","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.eucr.2025.103317_bib3","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.urolonc.2023.06.006","article-title":"Antibody-drug conjugates for urothelial carcinoma","volume":"41","author":"Thomas","year":"2023","journal-title":"Urol Oncol"},{"issue":"10","key":"10.1016\/j.eucr.2025.103317_bib4","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody\u2013drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.eucr.2025.103317_bib5","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/1078-0432.CCR-20-2275","article-title":"FDA approval summary: Enfortumab vedotin for locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Chang","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.eucr.2025.103317_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40265-019-01241-7","article-title":"Clinical overview of enfortumab vedotin in the management of locally advanced or metastatic urothelial carcinoma","volume":"80","author":"Hanna","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.eucr.2025.103317_bib7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jdcr.2020.10.020","article-title":"A rare presentation of enfortumab vedotin\u2013induced toxic epidermal necrolysis","volume":"7","author":"Francis","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"6","key":"10.1016\/j.eucr.2025.103317_bib8","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1586\/eci.11.66","article-title":"The current understanding of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"7","author":"Mockenhaupt","year":"2011","journal-title":"Expet Rev Clin Immunol"},{"issue":"19","key":"10.1016\/j.eucr.2025.103317_bib9","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.eucr.2025.103317_bib10","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.jaad.2020.11.067","article-title":"Clinicopathologic characterization of enfortumab vedotin\u2013associated cutaneous toxicity in patients with urothelial carcinoma","volume":"85","author":"Hirotsu","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.eucr.2025.103317_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.621591","article-title":"Enfortumab vedotin for metastatic urothelial carcinoma: a case series on the clinical and histopathologic spectrum of adverse cutaneous reactions from fatal Stevens-Johnson syndrome\/toxic epidermal necrolysis to dermal hypersensitivity reaction","volume":"11","author":"Viscuse","year":"2021","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.eucr.2025.103317_bib12","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/bjd.14530","article-title":"Guidelines for the management of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis in adults 2016","volume":"174","author":"Creamer","year":"2016","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.eucr.2025.103317_bib13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/iju5.12562","article-title":"Toxic epidermal necrolysis after the administration of enfortumab vedotin for urinary bladder urothelial carcinoma","volume":"6","author":"Mimura","year":"2022","journal-title":"IJU Case Rep"},{"key":"10.1016\/j.eucr.2025.103317_bib14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jdcr.2023.10.025","article-title":"Enfortumab vedotin toxic epidermal necrolysis-like blistering dermatosis: a case series and review of the literature","volume":"43","author":"Khanjar","year":"2023","journal-title":"JAAD Case Rep"},{"issue":"6","key":"10.1016\/j.eucr.2025.103317_bib15","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/PPO.0000000000000626","article-title":"Toxicities from antibody\u2013drug conjugates","volume":"28","author":"Johns","year":"2022","journal-title":"Cancer J"},{"issue":"2","key":"10.1016\/j.eucr.2025.103317_bib16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41585-020-00394-5","article-title":"The biology and rationale of targeting nectin-4 in urothelial carcinoma","volume":"18","author":"Heath","year":"2021","journal-title":"Nat Rev Urol"},{"issue":"11","key":"10.1016\/j.eucr.2025.103317_bib17","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/cup.14689","article-title":"Enfortumab vedotin\u2013induced cutaneous eruption: ring mitotic figures as a distinctive histopathologic feature","volume":"51","author":"Sport","year":"2024","journal-title":"J Cutan Pathol"}],"container-title":["Urology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214442025003882?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214442025003882?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T04:18:12Z","timestamp":1768277892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214442025003882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":17,"alternative-id":["S2214442025003882"],"URL":"https:\/\/doi.org\/10.1016\/j.eucr.2025.103317","relation":{},"ISSN":["2214-4420"],"issn-type":[{"value":"2214-4420","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early-onset fatal toxic epidermal necrolysis after first-cycle enfortumab vedotin in an elderly patient with metastatic urothelial carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eucr.2025.103317","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103317"}}